Knight Therapeutics Inc.
TSX : GUD

Knight Therapeutics Inc.

November 17, 2015 08:00 ET

Knight to Present at the TD Securities Technology & Healthcare Conference in Toronto

MONTREAL, CANADA--(Marketwired - Nov. 17, 2015) - Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, announced today that Jonathan Ross Goodman, President & CEO, is scheduled to present a corporate update at the TD Securities Technology & Healthcare Conference on Friday, November 20, 2015 at 10:00 am ET at the St. Andrew's Club & Conference Centre in Toronto. A copy of the presentation will be available at www.gud-knight.com.

Notice of Fourth Quarter and Year End 2015 Financial Results

Knight expects to release its fourth quarter and year end 2015 financial results on Thursday, March 24, 2016. Knight expects to hold a conference call at 8:30 am ET on Thursday, March 24, 2016. All interested parties are cordially invited to attend. Investors and other interested parties may call 877-223-4471 (Operator Assisted Toll-Free) or 647-788-4922 (local or international).

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com.

Forward-Looking Statement

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2014. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law.

Contact Information